Objective: The definition of has been the subject of debate for decades, and a semantic ambiguity highlighted in a 2016 article in the remains. The current article replicates and extends the 2016 findings on alcohol use disorder (AUD) relapse definitions.
Method: We conducted a systematic review of 321 articles that examined relapse in patients with AUD, published from 2000 to 2019. Relapse definitions were extracted and a narrative review of definitions was conducted.
Results: One hundred and one different definitions of relapse were used in 251 (78%) of the reviewed articles. In 70 (22%) of articles, no definition of AUD relapse was provided. Fifty-three articles used diagnostic criteria (i.e., alcohol use after remission of AUD), whereas 99 articles defined relapse as "any alcohol use" or "any use of alcohol/drugs." Additional articles defined relapse by alcohol outcomes (e.g., percent drinking days), alcohol-related problems, or hospitalizations ( = 97). Only 12 articles described the time window of abstinence preceding a relapse. We observed relatively no meaningful intercontinental or time-related differences in relapse definitions, although the outcome "percent heavy drinking days" was used more frequently in recent studies.
Conclusions: A wide variety of relapse definitions were identified. Despite decades of research and discussion, there is still no widely accepted consensus definition of AUD relapse. We propose to shift the focus toward clinical continuous outcomes, course specifiers based on the number of AUD symptoms present, and quality-of-life-related criteria instead of using current dichotomous AUD relapse terminology.
Download full-text PDF |
Source |
---|
Eur Arch Otorhinolaryngol
January 2025
Otorhinolaryngology, Head and Neck Surgery, University Hospitals Leuven, Leuven, Belgium.
Introduction: First branchial cleft anomalies (FBCA) are rare congenital head and neck malformations, often subject to incorrect diagnosis and treatment. We present our experience with FBCA, focusing on clinical presentation, diagnosis, perioperative relation to the facial nerve, surgical approach, complications and patient satisfaction.
Methods: A consecutive cohort of 16 patients undergoing surgical treatment for FBCA between 1999 and 2021 was analyzed.
Eur J Nucl Med Mol Imaging
January 2025
Department of Nuclear Medicine and Minnan PET Center, Xiamen Key Laboratory of Radiopharmaceuticals, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Purpose: To evaluate the diagnostic accuracy and clinical impact of fibroblast activation protein (FAP)-targeted PET/CT imaging in primary and metastatic breast cancer and compare the results with those of standard-of-care imaging (SCI) and [F]FDG PET/CT.
Methods: We prospectively analyzed patients with diagnosed or suspected breast cancer who underwent concomitant FAP-targeted PET/CT (radiotracers including either [Ga]Ga-FAPI-46 or [F]FAPI-42) and [F]FDG PET/CT scans from June 2020 to January 2024 at two medical centers. Breast ultrasound (US) imaging was performed in all treatment-naïve patients as SCI.
J Craniofac Surg
January 2025
Department of Plastic and Reconstructive Surgery, Plastic Surgery Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Shijingshan District, Beijing, China.
Reconstructing severe cervical scar contractures (SCSC) remains a considerable challenge. This study presents a novel approach to SCSC reconstruction using a combination of pre-expanded bipedicled forehead and lower trapezius musculocutaneous flaps. A retrospective analysis was conducted on 25 patients who underwent this procedure between April 2004 and July 2020.
View Article and Find Full Text PDFInt J Gynecol Cancer
January 2025
Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland. Electronic address:
Objective: This systematic review analyzed phase III trials in platinum-resistant ovarian cancer to understand their poor outcomes and guide future trials.
Methods: A systematic review adhering to PRISMA guidelines was conducted. PubMed/Medline, Cochrane Library CENTRAL, and EMBASE were searched for randomized phase III trials (2010-January 2024) involving patients with platinum-resistant ovarian cancer.
Am J Clin Oncol
January 2025
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.
Objectives: Cutaneous adnexal carcinomas (CACs) are rare skin cancers with no established treatment guidelines. Given the limited data, this study aims to explore the characteristics and outcomes of patients with CAC treated with radiation therapy (RT).
Methods: Patients diagnosed with CAC between 2000 and 2020 who received RT were included.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!